Celularity Announces Halal Certification of its Advanced Cellular Therapeutics, Biomaterial Products and Business ModelBusiness Wire • 12/05/22
Down 35.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Celularity, Inc. (CELU)Zacks Investment Research • 11/22/22
Imugene's onCARlytics combination with Celularity's placental-derived off-the-shelf allogeneic CYCART-19 T cells preclinical data presented at SITC Annual MeetingGlobeNewsWire • 11/10/22
Celularity Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/10/22
Celularity Presents Preclinical Data on CYNK-101, its Allogeneic Genetically-Modified Natural Killer Cell Therapy Candidate, at the Society for Immunotherapy of Cancer's 37th Annual MeetingGlobeNewsWire • 11/10/22
Celularity Publishes New Data in Frontiers in Immunology Demonstrating Placental-derived Natural Killer Cells (CYNK) Recognized and Eliminated Influenza A Virus (IAV)-infected Cells In VitroGlobeNewsWire • 09/26/22
Celularity Enters Into $150 Million Pre-Paid Advance Agreement with YorkvilleGlobeNewsWire • 09/15/22
Celularity Reports Second Quarter 2022 Financial Results and Corporate UpdateGlobeNewsWire • 08/09/22
Celularity Announces Treatment of First Patient in Phase 1/2a Clinical Trial for NK Cell Therapy CYNK-101, in Development for the First-Line Treatment of Advanced HER2 Positive Gastric and Gastroesophageal Junction (G/GEJ) CancersGlobeNewsWire • 07/27/22
Antengene Announces Research Collaboration with Celularity to Evaluate the Potential Therapeutic Synergy of Combining Antengene's Best-in-Class Bispecific Antibody with Celularity's Natural Killer Cell PlatformPRNewsWire • 07/19/22
Celularity To Be Added To The Russell 3000® Index And The Small-Cap Russell 2000®GlobeNewsWire • 06/08/22
Celularity Inc. Announces $30 Million Private Placement Priced At-The-Market Under Nasdaq RulesGlobeNewsWire • 05/18/22
Celularity Reports First Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/16/22